Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, discusses the importance of targeting proliferanting and quiescent chronic lymphocytic leukemia (CLL) cells.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.